このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

シロシビン補助ランダム化療法

2026年9月28日 更新者:Anna Wise、Emory University

PTSDに対するサイロシビン(サポート付き)および集中長期曝露療法の安全性と受容性

This pilot study will examine the safety, tolerability, acceptability, and efficacy of combination psilocybin + psychotherapy to decrease PTSD symptoms. Participants will be randomized into two different treatment groups, allowing the investigators to directly compare PE augmented with psilocybin and psilocybin-assisted psychotherapy.

調査の概要

詳細な説明

The Primary objective is to pilot and investigate tolerability, safety, and acceptability of psilocybin-assisted supportive therapy and psilocybin-assisted massed prolonged exposure (PE) therapy and conduct exploratory analyses related to comparative effectiveness of these treatments, including preliminary outcomes from pre-treatment to 1-month follow-up on post-traumatic stress disorder (PTSD) symptoms. Safety and tolerability of the treatment will be assessed and evaluated using the Swiss Psychedelic Side Effects Inventory (SPSI), Psychedelic-assisted Therapy After Effects (PATAE), and the Accessibility Questionnaire (AQ).

The study will also evaluate the effect of psilocybin and massed exposure therapy using Subjective Units of Distress (SUDS) during imaginal exposure sessions; to assess self-reported PTSD and depression symptoms across treatment and investigate effect on fear extinction learning and fear extinction recall as assessed via fear potentiated startle. Given that this is a pilot study with small sample, analyses will be preliminary.

研究の種類

介入

入学 (推定)

150

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Jessica Maples-Keller, PhD
  • 電話番号:404-778-2075
  • メール:jmaple2@emory.edu

研究連絡先のバックアップ

研究場所

    • Georgia
      • Atlanta、Georgia、アメリカ、30322
        • 募集
        • Emory University Hospital
        • コンタクト:
          • Jessica Maples-Keller, PhD
          • 電話番号:404-778-2075
          • メール:jmaple2@emory.edu
        • 主任研究者:
          • Anna Wise, PhD
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Eligible participants must be over the age of 18. They must self-identify as military veterans, reservists, National Guard members, or active-duty servicemembers. Additionally, they must be seeking treatment for PTSD, which will be confirmed by a CAPS-5-R assessment. The criteria below will be applicable to all participants, regardless of study treatment arm.

Inclusion Criteria

  1. Meet criteria for PTSD due to trauma occurring at least 3 months prior based on CAPS-5-R diagnostic scoring rules.
  2. Able to speak and read English (due to standardization of outcome measures).
  3. Willingness of participant to sign a release for the investigators to communicate with their primary care or mental health providers, if indicated
  4. Are 18 years and older.
  5. Are able to swallow pills.
  6. Agree to have study visits video and/or audio recorded, including Medicine Session, Independent Rater assessments, and non-drug psychotherapy sessions.
  7. Must provide a contact (relative, spouse, close friend, or other support person) who is willing and able to be reached by the investigators in the event of a participant becoming suicidal or unreachable.
  8. Must agree to inform the investigators within 48 hours of any medical conditions and procedures.
  9. If able to become pregnant, participants must have a negative pregnancy test prior to study entry, at study entry, and prior to each Medicine Session. They must agree to use highly effective birth control for a month prior to the Medicine session and through 10 days after the Medicine session.
  10. Agree to the following lifestyle modifications: comply with requirements for fasting and refraining from certain medications prior to Medicine Session, not participate in any other interventional clinical trials during the duration of the treatment, and agree not to operate their vehicles (or heavy machinery) up to 24 hours after Medicine Session, and commit to medication dosing, therapy, and study procedures.

Exclusion Criteria

  1. Are not able to give adequate informed consent.

  2. Have a family history bipolar disorder type 1 or a psychotic disorder in first degree relatives.

  3. Have any current problem which, in the opinion of the investigator or Medical Monitor, might interfere with participation.

  4. Have hypersensitivity to any ingredient of the IMP (Investigational Medicinal Product).

  5. Have a history of or current bipolar type 1 disorder, primary psychotic disorder (e.g., schizophrenia), or secondary psychotic features (i.e., Major Depressive disorder with psychotic features.

  6. Have met criteria at any time during their life for amphetamine or cocaine substance use disorder or any drug of abuse the study physician determines to be unfit for the study.

  7. Meet criteria for current (past 3 months) moderate or severe substance use disorder, as defined by 4 or more DSM SUD criteria symptoms.

  8. Have a positive screen for any drug of abuse (amphetamines, etc.) on drug test administered in local community or on site unless being taken as prescribed by a physician.

  9. Any participant presenting current serious suicide risk, as determined through psychiatric interview and clinical judgment of the investigator will be excluded;

    1. Suicidal ideation score of 4 or greater within the last 6 months.
    2. Any suicidal behavior, including suicide attempts or preparatory acts, within the last 6 months of the assessment
    3. However, history of suicide attempts is not an exclusion.
  10. Require ongoing concomitant therapy with a psychiatric medication with exceptions described in protocol section on Concomitant Medications.

    Medical History

  11. Have a history of any medical condition that could make receiving a sympathomimetic drug harmful because of increases in blood pressure and heart rate, or any medical condition the study physician believes would pose a safety risk or interfere with the effects of the treatment.

    1. This includes, but is not limited to, a history of myocardial infarction, cerebrovascular accident, or aneurysm.
    2. Participants with other stable chronic medical problems may be enrolled if the site physician believes would not significantly increase the risk of Psilocybin administration or be likely to produce significant symptoms during the study that could interfere with study participation or be confused with side effects of the IMP.
  12. Have any unstable medical or central nervous system-related illness that would interfere with participation.

  13. Systolic blood pressure >= 140 mmHg or diastolic blood pressure >= 90 mmHg, measured in the supine position after at least five minutes at rest. If the initial blood pressure is >= 140/90 mmHg, up to three additional attempts before dosing visit are permitted. The study physician will manage blood pressure monitoring from baseline through 10 days after drug administration.

  14. Have a history of clinically significant arrhythmia, other than premature atrial contractions (PACs) or occasional PVCs in the absence of ischemic heart disease, within 12 months of screening.

    a. Participants with a history of atrial fibrillation, atrial tachycardia, atrial flutter or paroxysmal supraventricular tachycardia or any other arrhythmia associated with a bypass tract may be enrolled only if they have been successfully treated with ablation and have not had recurrent arrhythmia for at least one year off all antiarrhythmic drugs and confirmed by a cardiologist.

  15. Have a marked Baseline prolongation of QT/QTc interval e.g., repeated demonstration of a QTc interval > 450 milliseconds (ms) in males and >470 ms in females. For transgender or non-binary participants, QTc interval will be evaluated based on sex assigned at birth.

  16. Have a history of additional risk factors for Torsade de pointes (e.g., heart failure, family history of Long QT Syndrome).

  17. Have significant liver enzyme elevations as evidenced by total bilirubin >1.5mg/dL and/or ALT and AST (>two times upper limit of normal [ULN]) per baseline laboratory test.

  18. Creatinine clearance: <30 mL/min)

  19. Non-ambulatory or require two-person assistance with transfers (Fall risk)

  20. Body Mass Index (BMI) <18

  21. Are pregnant or nursing

  22. fMRI Scan Exclusions Only: History of cranial surgery, metallic particles in the eye or head (exclusive of mouth), implanted cardiac pacemaker or any intra-cardiac lines, implanted neurostimulators, intra-cranial implants (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or implanted medical pumps.

    1. NOTE: these ineligibility criteria preclude participants from undergoing a fmri scan but does not exclude them from the primary study participant and they may proceed without fMRI.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Group 1: Psilocybin combined with supportive therapy

All participants will receive a single 25 mg dose of psilocybin during the experimental session, which occurs during to their respective therapy model.

Then, participants will receive 2 support (integrative) therapy sessions that will be 1 week apart. In between these sessions, subjects will complete a series of online surveys to track treatment progress.

25 mg

他の名前:
  • 3-[2-(ジメチルアミノ)エチル]-1H-インドール-4-イル リン酸二水素塩

Treatment includes non-directive psychological support across the preparatory, dosing, and integration sessions. Preparatory sessions include psychoeducation regarding psilocybin's subjective effects and establish strategies for psilocybin related support, including boundaries around physical touch. Therapists encourage setting intention for dosing day, and practicing experiential exercises. Integration sessions include processing the participant's experience of their psilocybin administration session. Therapists will support participants in identifying activities for ongoing integration outside of sessions. The standard care for supportive therapy will be modeled in this study.

実験的:Group 2: Psilocybin combined with massed prolonged exposure (PE) therapy

All participants will receive a single 25 mg dose of psilocybin during the experimental session, followed by 10 prolonged exposure (PE) therapy sessions for 10 days. In between these sessions, participants will complete a series of online surveys to track treatment progress.

25 mg

他の名前:
  • 3-[2-(ジメチルアミノ)エチル]-1H-インドール-4-イル リン酸二水素塩

Prolonged Exposure (PE) Therapy will be conducted for 10 sessions. They will consist of repeated exposures to trauma memories (imaginal exposure) consistent with the manualized protocol for massed exposure therapy. Also consistent with this treatment manual, participants will listen to imaginal exposures and conduct in real life exposures outside of PE sessions for "homework". The standard care for PE therapy will be modeled in this study.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change in PTSD symptoms based on CAPS-5-R total severity score
時間枠:Baseline, 1-month post-intervention

PTSD symptoms will be evaluated using the Revised Clinician-Administered PTSD Scale for DSM-5, that refers to 20 core symptoms as CAPS-5, each rated on a 0-4 severity scale (0 = absent to 4 = extremely severe), combining frequency and intensity. Total possible score range is 0 to 80 with higher scores correlating with worse outcome.

Baseline, 1-month post-intervention
Change in PCL-5 score
時間枠:Baseline, 1, 6 and 12 months post-intervention

The PCL-5 is a 20-item self-report measure of DSM-5 PTSD symptoms. Scores on the PCL range from 0 to 80, with higher scores indicating higher symptom severity, and a cutoff of 33 indicating clinical levels of PTSD symptoms.

Baseline, 1, 6 and 12 months post-intervention
Depression symptoms (PHQ-9)
時間枠:Baseline, 1, 6 and 12 months post-intervention

The PHQ-9 is a 9-item self-report measure of depressive symptoms. A score of 10 or above indicative of a possible major depressive episode, and it provides a measure of severity of these symptoms. Total possible score range is 0-29, higher score correlates with worse outcome.

Baseline, 1, 6 and 12 months post-intervention

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Anna Wise, PhD、Emory University

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年6月8日

一次修了 (推定)

2027年3月1日

研究の完了 (推定)

2027年3月1日

試験登録日

最初に提出

2026年1月8日

QC基準を満たした最初の提出物

2026年1月8日

最初の投稿 (実際)

2026年1月12日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月1日

QC基準を満たした最後の更新が送信されました

2026年9月28日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する